Salmi M, Grön-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S
National Public Health Institute, MediCity Unit, Turku, Finland.
J Cell Biol. 1993 Jul;122(2):431-42. doi: 10.1083/jcb.122.2.431.
CD44 is a family of glycoproteins involved in cell-cell and cell-matrix interactions. In addition to the major 90-kD form present on most hematopoietic cells, larger 140-230 kD forms are found on keratinocytes and carcinoma cell lines. These bigger isoforms of CD44 arise by alternative splicing that results in insertion of one or more of the "variant" exons into the extracellular part of the 90-kD constant form of the molecule. In rat, v6 (variant exon v6) containing form of CD44 confers metastatic potential to carcinoma cells, and therefore, it is of interest to study the distribution of this isoform in humans. We raised antibodies against a synthetic peptide containing a sequence encoded by the exon v6. A mAb thus obtained (designated Var3.1) strongly reacted with the plasma membranes of squamous cells in upper layers of skin and tonsil surface epithelia. Weaker staining was seen in germinal centers, vascular endothelia and enterocytes. Exon v6 containing forms of CD44 (CD44v6) were absent from tissue leukocytes and connective tissue components. In comparison, Hermes-3 epitope (on the constant part) containing forms of CD44 were preferentially localized in basal layers of epithelia, present on the surface on most leukocytes and connective tissue cells, and undetectable on the luminal surface of high endothelial venules. In benign neoplasms, epithelial cells stained with mAb Var3.1 like in normal tissues. In contrast, immunostaining of 30 squamous carcinoma specimens (both primary and metastatic lesions) revealed that malignant transformation resulted in downregulation or disappearance of Var3.1 epitope, but in majority of cases, not in diminished synthesis of the Hermes-3 epitope. Biochemical analyses showed that mAb Var3.1 recognized two major forms of CD44 (220 and 300 kD). In conclusion, epitopes on exon v6 and constant part of CD44 are differentially synthesized and regulated during normal and malignant growth of cells in man.
CD44是一族参与细胞间和细胞与基质相互作用的糖蛋白。除了大多数造血细胞上存在的主要90-kD形式外,在角质形成细胞和癌细胞系中还发现了更大的140-230 kD形式。CD44的这些更大的异构体是通过可变剪接产生的,可变剪接导致一个或多个“可变”外显子插入到该分子90-kD恒定形式的细胞外部分。在大鼠中,含v6(可变外显子v6)形式的CD44赋予癌细胞转移潜能,因此,研究该异构体在人类中的分布很有意义。我们制备了针对含外显子v6编码序列的合成肽的抗体。由此获得的一种单克隆抗体(命名为Var3.1)与皮肤上层鳞状细胞和扁桃体表面上皮细胞的质膜强烈反应。在生发中心、血管内皮细胞和肠上皮细胞中可见较弱的染色。含外显子v6形式的CD44(CD44v6)在组织白细胞和结缔组织成分中不存在。相比之下,含Hermes-3表位(在恒定部分)形式的CD44优先定位于上皮的基底层,存在于大多数白细胞和结缔组织细胞的表面,而在高内皮微静脉的管腔表面检测不到。在良性肿瘤中,上皮细胞像在正常组织中一样用单克隆抗体Var3.1染色。相反,对30例鳞状癌标本(原发和转移病变)的免疫染色显示,恶性转化导致Var3.1表位下调或消失,但在大多数情况下,Hermes-3表位的合成并未减少。生化分析表明,单克隆抗体Var3.1识别两种主要形式的CD44(220和300 kD)。总之,在人类细胞的正常和恶性生长过程中,CD44外显子v6和恒定部分的表位在合成和调控上存在差异。